Tissue-based gene expression testing in localized prostate cancer
Sivanesan N, Diaz G, Sprenkle P. Tissue-based gene expression testing in localized prostate cancer. Current Opinion In Urology 2025, 35: 432-438. PMID: 40314067, DOI: 10.1097/mou.0000000000001289.Peer-Reviewed Original ResearchConceptsLocalized prostate cancerTissue-based genomic testingProstate cancerRisk stratificationGenomic testingManagement of localized prostate cancerProstate cancer risk stratificationIdentified high-risk patientsClinically significant cancerProstate cancer outcomesImpact of genomic testingHigh-risk patientsAssess tumor aggressivenessLow-risk casesGenomic assaysGene expression testsTreatment decision-makingPSA levelsGleason scoreSignificant cancerOncotype DXTumor aggressivenessTherapeutic choiceReduce overtreatmentProspective studyCharacterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
Zampini M, Riva E, Lanino L, Sauta E, Dos Reis R, Ejarque R, Maggioni G, Termanini A, Merlotti A, Campagna A, Dall’Olio L, Kulasekararaj A, Calvi M, Di Vito C, Bonometti A, Rahal D, Croci G, Boveri E, Gianelli U, Ponzoni M, Caselli R, Albertazzi S, Todisco G, Ubezio M, Crisafulli L, Frigo A, Lugli E, Mosca E, Acha P, Ghisletti S, Nicassio F, Santoro A, Diez-Campelo M, Solé F, Ades L, Platzbecker U, Santini V, Fenaux P, Haferlach T, Sallman D, Garcia-Manero G, Mavilio D, Remondini D, Castellani G, D'Amico S, Zeidan A, Komrokji R, Kordasti S, Ficara F, Della Porta M, Consortium C, Russo A, Travaglino E, Delleani M, Asti G, Ventura D, Tentori C, Buizza A, Brindisi M, Pinocchio N, Pesce F. Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes. Journal Of Clinical Oncology 2025, 43: 2069-2083. PMID: 40315418, PMCID: PMC12169866, DOI: 10.1200/jco-24-02394.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeP53 dysfunctionPhenotype of immune cellsClassification of myeloid neoplasmsIdentified high-risk patientsImpaired antigen presentationOptimal timing of therapeutic interventionsAbnormal p53 proteinHigh-risk patientsSubsets of patientsBone marrow progenitorsTiming of therapeutic interventionDesign of clinical trialsRecognition of patientsTumor protein 53Variant allele frequencyNF-kB pathwayInnovative immunotherapyMyeloid neoplasmsDismal outcomeMarrow progenitorsImmune dysregulationBiallelic inactivationImmune cellsPoor prognosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply